miR-362-3p acts as a tumor suppressor by targeting SERBP1 in ovarian cancer

Abstract

Background Ovarian cancer is the leading lethal gynecological cancer and is generally diagnosed during late-stage presentation. In addition, patients with ovarian cancer still face a low 5-year survival rate. Thus, innovative molecular targeting agents are required to overcome this disease. The present study aimed to explore the function of miR-362-3p and the underlying molecular mechanisms influencing ovarian cancer progression. Methods The expression levels of miR-362-3p were determined using qRT-PCR. Gain-of-function and loss-of-function methods were used to detect the effects of miR-362-3p on cell proliferation, cell migration, and tumor metastasis in ovarian cancer. A luciferase reporter assay was performed to confirm the potential target of miR-362-3p, and a rescue experiment was employed to verify the effect of miR-362-3p on ovarian cancer by regulating its target gene. Results miR-362-3p was significantly downregulated in ovarian cancer tissues and cell lines. In vitro, our data showed that miR-362-3p suppressed cell proliferation and migration. In vivo, miR-362-3p inhibited ovarian cancer growth and metastasis. Mechanistically, SERBP1 was identified as a direct target and functional effector of miR-362-3p in ovarian cancer. Moreover, SERBP1 overexpression rescued the biological function of miR-362-3p. Conclusions Our data reveal that miR-362-3p has an inhibitory effect on ovarian cancer. miR-362-3p inhibits the development and progression of ovarian cancer by directly binding its target gene SERBP1.

miR-362-3p suppresses ovarian cancer by inhibiting LRP8

“…Regarding ovarian cancer, only one study revealed that miR-362-3p levels were downregulated in the tissues and cells, which could suppress cell growth and migration by reducing MyD88 expression [10] . Additionally, recent studies have also shown that miR-362-3p inhibits ovarian cancer and inhibits the occurrence and development of ovarian cancer by directly binding its target gene, SERPINE1 mRNA-binding protein 1 ( SERBP1 ) [26] . Similar to a previous study, miR-362-3p levels were also significantly downregulated in ovarian cancer tissues and cells in our study.…”

Aberrant miR-362-3p is Associated with EBV-Infection and Prognosis in Nasopharyngeal Carcinoma and Involved in Tumor Progression by Targeting JMJD2A

“… 27 Cao et al have found the suppressive role of miR-362-3p in the function of ovarian cancer cells. 11 In breast cancer, miR-362-3p inhibits the cell proliferation. 28 Thus, we consider that miR-362-3p serves as a suppressor in NPC progression.…”

“… 8 There have been numerous studies reporting the important roles of miRNAs in human malignancies. 9 , 10 In addition, microRNA (miR)-362-3p has been found to function as a tumor suppressor in multiple tumor diseases, such as ovarian cancer, 11 epithelial ovarian cancer 12 and cervical cancer. 13 However, its role in NPC remains unknown.…”

Treatment of microvascular invasion in hepatocellular carcinoma with drug‐loaded nanocomposite platform under synergistic effect of magnetic field/near‐infrared light

“…Cisplatin delivery based on nanocarriers is conductive to reducing drug-protein interaction to achieve selective accumulation on tumor sites. 52 In addition, the proportion in G0/G1 phase in the αCD97-USPIO-Au-DDP group increased more remarkably, because αCD97 modification enhanced the targeting of the compound drug to cancer cells. All the above, αCD97-USPIO-Au-DDP was capable of blocking cancer cells in G0/G1 phase to restrain cell proliferation.…”